Aditum Bio and Leads Biolabs Launch Oblenio Bio to Advance LBL-051 for Autoimmune Indications
Shots:
- Aditum Bio & Leads Biolabs have launched Oblenio Bio to develop LBL-051 targeting autoimmune indications, with Aditum funding the venture and both companies working to advance it into clinical evaluations
- Leads Biolabs gives Oblenio Bio an exclusive option for developing, manufacturing & commercializing LBL-051 globally, with Leads entitled to receive up to $35M in upfront & near-term payments, $579M in milestones, sales-based royalties and an equity stake
- LBL-051, developed on the LeadsBody Platform, is a tri-specific T-cell engager targeting CD19, BCMA & CD3. It is designed to improve safety & effectiveness by precisely adjusting the potency of each domain
Ref:Aditum Bio | Image: Aditum Bio & Leads Biolabs
Related News:- Leads Biolabs Secures the US FDA’s Orphan Drug Designation for LBL-034 to Treat Multiple Myeloma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
